: Participants from two completed, placebo-controlled, randomized trials of tesamorelin for central adiposity treatment in PLWH were included if they had either a clinical response to tesamorelin (VAT decrease ≥8%, ≈70% of participants) or were placebo-treated.
: CT VAT and subcutaneous fat (SAT) density (Hounsfield Units, HU) were measured by a central blinded reader.Results: Participants (193 responders, 148 placebo) were 87% male and 83% Caucasian. Baseline characteristics were similar across arms, including VAT (-91 HU both arms, p = 0.80) and SAT density (-94 HU tesamorelin, -95 HU placebo, p = 0.29). Over 26 weeks, mean (SD) VAT and SAT density increased in tesamorelin-treated participants only (VAT: + 6.2 (8.7) HU tesamorelin, + 0.3 (4.2) HU placebo, p < 0.0001; SAT: + 4.0 (8.7) HU tesamorelin, + 0.3 (4.8) HU placebo, p < 0.0001). The tesamorelin effects persisted after controlling for baseline VAT or SAT HU and area, and VAT (+2.3 HU, 95% CI [4.5, 7.3], p = 0.001) or SAT (+3.5 HU, 95% CI [2.3, 4.7], p < 0.001) area change.
: In PLWH with central adiposity who experienced VAT quantity reductions on tesamorelin, VAT and SAT density increased independent of changes in fat quantity, suggesting that tesamorelin also improves VAT and SAT quality in this group.
Copyright © 2021 Wolters Kluwer Health, Inc.